CA2923793C - Carbon dioxide and saline nasal delivery methods and delivery devices - Google Patents
Carbon dioxide and saline nasal delivery methods and delivery devices Download PDFInfo
- Publication number
- CA2923793C CA2923793C CA2923793A CA2923793A CA2923793C CA 2923793 C CA2923793 C CA 2923793C CA 2923793 A CA2923793 A CA 2923793A CA 2923793 A CA2923793 A CA 2923793A CA 2923793 C CA2923793 C CA 2923793C
- Authority
- CA
- Canada
- Prior art keywords
- dosage
- main housing
- carbon dioxide
- nasal
- dispenser head
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 title claims abstract description 240
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 title claims abstract description 123
- 229910002092 carbon dioxide Inorganic materials 0.000 title claims abstract description 117
- 239000001569 carbon dioxide Substances 0.000 title claims abstract description 116
- 239000011780 sodium chloride Substances 0.000 title claims abstract description 102
- 238000002716 delivery method Methods 0.000 title description 21
- 210000003928 nasal cavity Anatomy 0.000 claims abstract description 43
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 42
- 239000012530 fluid Substances 0.000 claims abstract description 39
- 210000003128 head Anatomy 0.000 claims description 99
- 238000011282 treatment Methods 0.000 claims description 92
- 206010019233 Headaches Diseases 0.000 claims description 10
- 231100000869 headache Toxicity 0.000 claims description 10
- 206010039083 rhinitis Diseases 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 8
- 210000001331 nose Anatomy 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 201000009240 nasopharyngitis Diseases 0.000 claims description 5
- 201000009890 sinusitis Diseases 0.000 claims description 5
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 43
- 230000001105 regulatory effect Effects 0.000 abstract description 11
- 239000007789 gas Substances 0.000 description 56
- 150000003839 salts Chemical class 0.000 description 31
- 239000003814 drug Substances 0.000 description 27
- 230000007246 mechanism Effects 0.000 description 18
- 239000002775 capsule Substances 0.000 description 14
- 238000010586 diagram Methods 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 201000010105 allergic rhinitis Diseases 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 208000006673 asthma Diseases 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 239000013566 allergen Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010039085 Rhinitis allergic Diseases 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 206010029216 Nervousness Diseases 0.000 description 5
- 208000036284 Rhinitis seasonal Diseases 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000003811 finger Anatomy 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 5
- 206010020591 Hypercapnia Diseases 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000004909 Moisturizer Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 210000000746 body region Anatomy 0.000 description 3
- 208000027744 congestion Diseases 0.000 description 3
- 239000000850 decongestant Substances 0.000 description 3
- 229940124581 decongestants Drugs 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003447 ipsilateral effect Effects 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 210000003813 thumb Anatomy 0.000 description 3
- 239000005526 vasoconstrictor agent Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010039094 Rhinitis perennial Diseases 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229960005475 antiinfective agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 208000027993 eye symptom Diseases 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000000133 nasal decongestant Substances 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 208000022719 perennial allergic rhinitis Diseases 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010040742 Sinus congestion Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 229950007554 levmetamfetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-SECBINFHSA-N levmetamfetamine Chemical compound CN[C@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-SECBINFHSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000000492 nasalseptum Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000008284 neuronal mechanism Effects 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960001262 tramazoline Drugs 0.000 description 1
- QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229960000833 xylometazoline Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
- A61M11/007—Syringe-type or piston-type sprayers or atomisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0031—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up by bursting or breaking the package, i.e. without cutting or piercing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0225—Carbon oxides, e.g. Carbon dioxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0618—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mechanical Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2013/000207 WO2015038092A2 (en) | 2013-09-10 | 2013-09-10 | Carbon dioxide and saline nasal delivery methods and delivery devices |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2923793A1 CA2923793A1 (en) | 2015-03-19 |
| CA2923793C true CA2923793C (en) | 2018-02-27 |
Family
ID=52666483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2923793A Active CA2923793C (en) | 2013-09-10 | 2013-09-10 | Carbon dioxide and saline nasal delivery methods and delivery devices |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3043650A4 (enExample) |
| JP (1) | JP2016529082A (enExample) |
| AU (1) | AU2013400183B2 (enExample) |
| CA (1) | CA2923793C (enExample) |
| MX (1) | MX2016002968A (enExample) |
| WO (1) | WO2015038092A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3013821C (en) * | 2016-02-05 | 2022-05-10 | Clover Hill Healthcare, Inc. | Nasal treatment delivery device with carbon dioxide and saline, and methods, including low flow rates |
| WO2020069528A1 (en) * | 2018-09-28 | 2020-04-02 | Achilleus LLC | Secure device for delivering medications |
| WO2020260416A1 (en) * | 2019-06-25 | 2020-12-30 | Philip Morris Products S.A. | Carbonated liquid nicotine formulation |
| GB2586301B (en) * | 2020-04-07 | 2021-08-25 | Splash Tm Gmbh | Stable-Foam inhalation Device and Cartridge |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06312019A (ja) * | 1993-04-30 | 1994-11-08 | Shinko Kagaku Kk | 薬液噴霧容器 |
| EP1218049B1 (en) * | 1999-07-12 | 2006-09-20 | Capnia Incorporated | Apparatus for relieving headaches, rhinitis and other common ailments |
| JP2003040766A (ja) * | 2001-07-26 | 2003-02-13 | Kao Corp | 鼻腔内洗浄具 |
| DE20121474U1 (de) * | 2001-09-26 | 2003-01-16 | Zellner, Gerhard, Dr., 83435 Bad Reichenhall | Flüssigkeit zur Prävention und zur Behandlung der Atemwege |
| IL160936A0 (en) * | 2004-02-05 | 2004-08-31 | Scott A Cordray | Nasal spray and wash |
| CN1669559A (zh) * | 2004-03-15 | 2005-09-21 | 刘展欣 | 用于治疗鼻炎的药品 |
| US7874467B2 (en) * | 2005-11-03 | 2011-01-25 | Reseal International Limited Partnership | Metered drop push button dispenser system |
| US7875001B2 (en) * | 2008-02-25 | 2011-01-25 | Americo Michael Minotti | Multi medication nasal spray device and method |
| JP5959269B2 (ja) * | 2011-05-10 | 2016-08-02 | 伸晃化学株式会社 | 噴霧容器 |
| US8778383B2 (en) * | 2011-06-07 | 2014-07-15 | Parion Sciences, Inc. | Methods of treatment |
| WO2013063413A1 (en) * | 2011-10-28 | 2013-05-02 | Ampio Pharmaceuticals, Inc. | Treatment of rhinitis |
| CN104220123B (zh) * | 2012-02-16 | 2017-08-25 | 卡普尼亚公司 | 带扩散鼻件的气体分配器 |
-
2013
- 2013-09-10 EP EP13893220.7A patent/EP3043650A4/en not_active Ceased
- 2013-09-10 JP JP2016541940A patent/JP2016529082A/ja active Pending
- 2013-09-10 CA CA2923793A patent/CA2923793C/en active Active
- 2013-09-10 MX MX2016002968A patent/MX2016002968A/es unknown
- 2013-09-10 WO PCT/US2013/000207 patent/WO2015038092A2/en not_active Ceased
- 2013-09-10 AU AU2013400183A patent/AU2013400183B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016529082A (ja) | 2016-09-23 |
| EP3043650A4 (en) | 2017-11-08 |
| WO2015038092A2 (en) | 2015-03-19 |
| AU2013400183A1 (en) | 2016-03-17 |
| AU2013400183B2 (en) | 2017-04-27 |
| WO2015038092A3 (en) | 2015-07-16 |
| MX2016002968A (es) | 2016-12-02 |
| CA2923793A1 (en) | 2015-03-19 |
| EP3043650A2 (en) | 2016-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9370632B2 (en) | Nasal treatment delivery device for mixed carbon dioxide and saline | |
| US10052464B2 (en) | Low flow rate nasal treatment delivery device for mixed carbon dioxide and saline | |
| JP4932109B2 (ja) | 頭痛、鼻炎及び他のありふれた病気を治す方法及び装置 | |
| JP5674637B2 (ja) | ガスミスト吸入器 | |
| US8398580B2 (en) | Methods and apparatus for treating rhinitis | |
| US20150374822A1 (en) | Methods and apparatus for the enhanced delivery of the physiologic agents to tissue surfaces | |
| JP5102376B2 (ja) | ガスミスト吸入器 | |
| JP2005503868A (ja) | 鼻ネブライザー | |
| CA2923793C (en) | Carbon dioxide and saline nasal delivery methods and delivery devices | |
| WO2004082633A3 (en) | A method of treating a systemic disease | |
| US20170296489A1 (en) | Cooling Adjunct For Medications To Treat Disorders In The Nasal Cavity | |
| US9272036B2 (en) | Carbon dioxide, saline and additional active nasal delivery methods and treatments | |
| US20170360831A1 (en) | Non-nasal treatment methods using carbon dioxide and saline | |
| US20170224936A1 (en) | Nasal treatment delivery device with carbon dioxide and saline, and methods | |
| CA3013821C (en) | Nasal treatment delivery device with carbon dioxide and saline, and methods, including low flow rates | |
| US10029054B2 (en) | Lower body cavity treatment methods and devices using carbon dioxide and saline | |
| US20130280348A1 (en) | Carbon dioxide and saline nasal delivery methods and treatments | |
| EP4100089B1 (en) | Kit for treating chronic and long-term nasal congestion | |
| US20220118202A1 (en) | Airway cleansing, allergy treatment and agent delivery method and apparatus | |
| CA2856862A1 (en) | Sprayable oxygenated saline composition and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160309 |
|
| EEER | Examination request |
Effective date: 20160309 |